Pain and Substance Use Disorder

New Flexibility for Physicians Managing Patients with Opioid Use Disorder

The Drug Enforcement Administration (DEA) has partnered with the Substance Abuse and Mental Health Services Administration (SAMHSA) to ensure authorized practitioners may admit and treat new patients with opioid use disorder during the current public health emergency. The DEA previously announced that practitioners can prescribe controlled substances via telemedicine with a prior in-person evaluation. This new guidance allows practitioners to prescribe buprenorphine via telephone without prior telemedicine examination. Read the full statement here.

 

Guidance on Buprenorphine and Methadone Treatment during COVID-19

The Substance Abuse Mental Health Services Administration has released guidance on buprenorphine and methadone treatment in the COVID-19 pandemic. Prescribing buprenorphine (suboxone/subutex) for opioid use disorder no longer requires an in-person evaluation, although providing methadone via a methadone clinic still does.

 


Join now

SIG Membership is open to all ASRA members. There is no cost to join. 

To join, login to your profile here and select your current membership in the lower left. From here, select “Add/Remove Sections” at the bottom of the page.


Pain and Substance Use Disorder SIG Community 

Mission and Goals of the Pain and Substance Use Disorder SIG

Members-Only Resources

Leadership & Founding Members

Get More Involved

See Other SIGs